Listed

Sangamo Therapeutics, Inc

SGMOQOTCCIK 1001233HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.4m, Q1 FY2026
Operating income−$31.9m, Q1 FY2026
Net income−$31.0m, Q1 FY2026
Sangamo Therapeutics, Inc, income statement, quarterly
Line itemUnitQ2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31
Revenue$m6.8Revenue, Q2 FY2023, three months to 2023-06-30$6.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure9.4Revenue, Q3 FY2023, three months to 2023-09-30$9.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure2.0Revenue, Q4 FY2023, three months to 2023-12-31$2.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-17, accession 0001628280-25-013088. Derived: 12-month figure less the 9-month figure.Report this figure0.5Revenue, Q1 FY2024, three months to 2024-03-31$481.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure0.4Revenue, Q2 FY2024, three months to 2024-06-30$356.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure49.4Revenue, Q3 FY2024, three months to 2024-09-30$49.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure7.6Revenue, Q4 FY2024, three months to 2024-12-31$7.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure6.4Revenue, Q1 FY2025, three months to 2025-03-31$6.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure18.3Revenue, Q2 FY2025, three months to 2025-06-30$18.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure0.6Revenue, Q3 FY2025, three months to 2025-09-30$581.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure14.2Revenue, Q4 FY2025, three months to 2025-12-31$14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure1.4Revenue, Q1 FY2026, three months to 2026-03-31$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Research and development$m63.0Research and development, Q2 FY2023, three months to 2023-06-30$63.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure57.1Research and development, Q3 FY2023, three months to 2023-09-30$57.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure50.7Research and development, Q4 FY2023, three months to 2023-12-31$50.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-17, accession 0001628280-25-013088. Derived: 12-month figure less the 9-month figure.Report this figure35.9Research and development, Q1 FY2024, three months to 2024-03-31$35.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure24.2Research and development, Q2 FY2024, three months to 2024-06-30$24.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure27.7Research and development, Q3 FY2024, three months to 2024-09-30$27.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure23.7Research and development, Q4 FY2024, three months to 2024-12-31$23.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure26.0Research and development, Q1 FY2025, three months to 2025-03-31$26.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure27.1Research and development, Q2 FY2025, three months to 2025-06-30$27.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure28.1Research and development, Q3 FY2025, three months to 2025-09-30$28.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure31.4Research and development, Q4 FY2025, three months to 2025-12-31$31.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure26.6Research and development, Q1 FY2026, three months to 2026-03-31$26.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Operating income$m(124)Operating income, Q2 FY2023, three months to 2023-06-30−$123.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure(106)Operating income, Q3 FY2023, three months to 2023-09-30−$106.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure(62.1)Operating income, Q4 FY2023, three months to 2023-12-31−$62.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-17, accession 0001628280-25-013088. Derived: 12-month figure less the 9-month figure.Report this figure(51.5)Operating income, Q1 FY2024, three months to 2024-03-31−$51.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure(37.1)Operating income, Q2 FY2024, three months to 2024-06-30−$37.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure10.6Operating income, Q3 FY2024, three months to 2024-09-30$10.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure(26.0)Operating income, Q4 FY2024, three months to 2024-12-31−$26.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure(29.6)Operating income, Q1 FY2025, three months to 2025-03-31−$29.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure(17.9)Operating income, Q2 FY2025, three months to 2025-06-30−$17.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure(35.6)Operating income, Q3 FY2025, three months to 2025-09-30−$35.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure(38.2)Operating income, Q4 FY2025, three months to 2025-12-31−$38.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure(31.9)Operating income, Q1 FY2026, three months to 2026-03-31−$31.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Income tax$m(6.3)Income tax, Q2 FY2023, three months to 2023-06-30−$6.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure1.3Income tax, Q3 FY2023, three months to 2023-09-30$1.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure(0.3)Income tax, Q4 FY2023, three months to 2023-12-31−$272.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-17, accession 0001628280-25-013088. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2024, three months to 2024-03-31$98.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure0.1Income tax, Q2 FY2024, three months to 2024-06-30$74.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure0.1Income tax, Q3 FY2024, three months to 2024-09-30$88.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure(0.4)Income tax, Q4 FY2024, three months to 2024-12-31−$427.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure0.1Income tax, Q1 FY2025, three months to 2025-03-31$119.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$27.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure(0.2)Income tax, Q3 FY2025, three months to 2025-09-30−$161.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure(0.6)Income tax, Q4 FY2025, three months to 2025-12-31−$553.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Net income$m(115)Net income, Q2 FY2023, three months to 2023-06-30−$114.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure(104)Net income, Q3 FY2023, three months to 2023-09-30−$104.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure(60.3)Net income, Q4 FY2023, three months to 2023-12-31−$60.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-17, accession 0001628280-25-013088. Derived: 12-month figure less the 9-month figure.Report this figure(49.1)Net income, Q1 FY2024, three months to 2024-03-31−$49.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure(36.1)Net income, Q2 FY2024, three months to 2024-06-30−$36.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure10.7Net income, Q3 FY2024, three months to 2024-09-30$10.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure(23.4)Net income, Q4 FY2024, three months to 2024-12-31−$23.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure(30.6)Net income, Q1 FY2025, three months to 2025-03-31−$30.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure(20.0)Net income, Q2 FY2025, three months to 2025-06-30−$20.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure(34.9)Net income, Q3 FY2025, three months to 2025-09-30−$34.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure(37.4)Net income, Q4 FY2025, three months to 2025-12-31−$37.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure(31.0)Net income, Q1 FY2026, three months to 2026-03-31−$31.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Diluted EPS$ per share(0.66)Diluted EPS, Q2 FY2023, three months to 2023-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure(0.59)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figurenot reported(0.27)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure(0.18)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure0.04Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figurenot reported(0.14)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure(0.08)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure(0.11)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figurenot reported(0.08)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Basic EPS$ per share(0.66)Basic EPS, Q2 FY2023, three months to 2023-06-30−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure(0.59)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.59 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figurenot reported(0.27)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.27 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure(0.18)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure0.05Basic EPS, Q3 FY2024, three months to 2024-09-30$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figurenot reported(0.14)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure(0.08)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure(0.11)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.11 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figurenot reported(0.08)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure

Balance sheet

Cash and equivalents$27.6m, Q1 FY2026
Shareholders' equity−$19.0m, Q1 FY2026
Sangamo Therapeutics, Inc, balance sheet, quarterly
Line itemUnitQ2 FY20232023-06-30Q3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31
Cash and equivalents$m66.8Cash and equivalents, Q2 FY2023, at 2023-06-30$66.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure56.5Cash and equivalents, Q3 FY2023, at 2023-09-30$56.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure45.2Cash and equivalents, FY2023, at 2023-12-31$45.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure54.4Cash and equivalents, Q1 FY2024, at 2024-03-31$54.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure27.8Cash and equivalents, Q2 FY2024, at 2024-06-30$27.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure39.2Cash and equivalents, Q3 FY2024, at 2024-09-30$39.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure41.9Cash and equivalents, FY2024, at 2024-12-31$41.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure25.2Cash and equivalents, Q1 FY2025, at 2025-03-31$25.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure38.3Cash and equivalents, Q2 FY2025, at 2025-06-30$38.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure29.6Cash and equivalents, Q3 FY2025, at 2025-09-30$29.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure20.9Cash and equivalents, FY2025, at 2025-12-31$20.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure27.6Cash and equivalents, Q1 FY2026, at 2026-03-31$27.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Current assets$m160Current assets, Q2 FY2023, at 2023-06-30$159.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-08-08, accession 0001628280-23-028200.Report this figure148Current assets, Q3 FY2023, at 2023-09-30$147.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-01, accession 0001628280-23-035989.Report this figure94.3Current assets, FY2023, at 2023-12-31$94.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-17, accession 0001628280-25-013088.Report this figure68.6Current assets, Q1 FY2024, at 2024-03-31$68.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001628280-24-022194.Report this figure40.1Current assets, Q2 FY2024, at 2024-06-30$40.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure58.1Current assets, Q3 FY2024, at 2024-09-30$58.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure51.7Current assets, FY2024, at 2024-12-31$51.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-30, accession 0001628280-26-022029.Report this figure37.6Current assets, Q1 FY2025, at 2025-03-31$37.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure49.9Current assets, Q2 FY2025, at 2025-06-30$49.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure44.1Current assets, Q3 FY2025, at 2025-09-30$44.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure35.8Current assets, FY2025, at 2025-12-31$35.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure37.1Current assets, Q1 FY2026, at 2026-03-31$37.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Total assets$m325Total assets, Q2 FY2023, at 2023-06-30$325.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-08-08, accession 0001628280-23-028200.Report this figure220Total assets, Q3 FY2023, at 2023-09-30$219.7m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-01, accession 0001628280-23-035989.Report this figure165Total assets, FY2023, at 2023-12-31$165.3m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-17, accession 0001628280-25-013088.Report this figure129Total assets, Q1 FY2024, at 2024-03-31$129.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001628280-24-022194.Report this figure93.0Total assets, Q2 FY2024, at 2024-06-30$93.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure111Total assets, Q3 FY2024, at 2024-09-30$111.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure102Total assets, FY2024, at 2024-12-31$101.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-30, accession 0001628280-26-022029.Report this figure86.2Total assets, Q1 FY2025, at 2025-03-31$86.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure97.6Total assets, Q2 FY2025, at 2025-06-30$97.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure88.6Total assets, Q3 FY2025, at 2025-09-30$88.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure59.7Total assets, FY2025, at 2025-12-31$59.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure60.0Total assets, Q1 FY2026, at 2026-03-31$60.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Current liabilities$m53.8Current liabilities, Q2 FY2023, at 2023-06-30$53.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-08-08, accession 0001628280-23-028200.Report this figure48.5Current liabilities, Q3 FY2023, at 2023-09-30$48.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-01, accession 0001628280-23-035989.Report this figure47.7Current liabilities, FY2023, at 2023-12-31$47.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-17, accession 0001628280-25-013088.Report this figure40.2Current liabilities, Q1 FY2024, at 2024-03-31$40.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001628280-24-022194.Report this figure39.0Current liabilities, Q2 FY2024, at 2024-06-30$39.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure43.2Current liabilities, Q3 FY2024, at 2024-09-30$43.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure45.8Current liabilities, FY2024, at 2024-12-31$45.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-30, accession 0001628280-26-022029.Report this figure49.6Current liabilities, Q1 FY2025, at 2025-03-31$49.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure47.7Current liabilities, Q2 FY2025, at 2025-06-30$47.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure50.1Current liabilities, Q3 FY2025, at 2025-09-30$50.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure42.5Current liabilities, FY2025, at 2025-12-31$42.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure53.1Current liabilities, Q1 FY2026, at 2026-03-31$53.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Total liabilities$m91.4Total liabilities, Q2 FY2023, at 2023-06-30$91.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-08-08, accession 0001628280-23-028200.Report this figure84.8Total liabilities, Q3 FY2023, at 2023-09-30$84.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-01, accession 0001628280-23-035989.Report this figure82.4Total liabilities, FY2023, at 2023-12-31$82.4m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-17, accession 0001628280-25-013088.Report this figure72.3Total liabilities, Q1 FY2024, at 2024-03-31$72.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001628280-24-022194.Report this figure69.3Total liabilities, Q2 FY2024, at 2024-06-30$69.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure72.1Total liabilities, Q3 FY2024, at 2024-09-30$72.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure78.9Total liabilities, FY2024, at 2024-12-31$78.9m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-30, accession 0001628280-26-022029.Report this figure81.3Total liabilities, Q1 FY2025, at 2025-03-31$81.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure78.0Total liabilities, Q2 FY2025, at 2025-06-30$78.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure82.4Total liabilities, Q3 FY2025, at 2025-09-30$82.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure74.0Total liabilities, FY2025, at 2025-12-31$74.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure78.9Total liabilities, Q1 FY2026, at 2026-03-31$78.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Shareholders' equity$m234Shareholders' equity, Q2 FY2023, at 2023-06-30$233.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure135Shareholders' equity, Q3 FY2023, at 2023-09-30$134.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure82.9Shareholders' equity, FY2023, at 2023-12-31$82.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-30, accession 0001628280-26-022029.Report this figure56.7Shareholders' equity, Q1 FY2024, at 2024-03-31$56.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure23.7Shareholders' equity, Q2 FY2024, at 2024-06-30$23.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure39.1Shareholders' equity, Q3 FY2024, at 2024-09-30$39.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure22.8Shareholders' equity, FY2024, at 2024-12-31$22.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure4.9Shareholders' equity, Q1 FY2025, at 2025-03-31$4.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure19.6Shareholders' equity, Q2 FY2025, at 2025-06-30$19.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure6.2Shareholders' equity, Q3 FY2025, at 2025-09-30$6.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure(14.3)Shareholders' equity, FY2025, at 2025-12-31−$14.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure(19.0)Shareholders' equity, Q1 FY2026, at 2026-03-31−$19.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure

Cash flow

Operating cash flow−$19.3m, Q1 FY2026
Capital expenditure$13.0k, Q1 FY2026
Sangamo Therapeutics, Inc, cash flow, quarterly
Line itemUnitQ2 FY20232023-06-30Q3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31
Operating cash flow$m(60.7)Operating cash flow, Q2 FY2023, three months to 2023-06-30−$60.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-08-06, accession 0001628280-24-035165. Derived: 6-month figure less the 3-month figure.Report this figure(47.3)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$47.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001628280-24-047102. Derived: 9-month figure less the 6-month figure.Report this figure(50.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$50.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-17, accession 0001628280-25-013088. Derived: 12-month figure less the 9-month figure.Report this figure(48.7)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$48.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure(26.9)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$26.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001628280-25-038860. Derived: 6-month figure less the 3-month figure.Report this figure11.8Operating cash flow, Q3 FY2024, three months to 2024-09-30$11.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001001233-25-000024. Derived: 9-month figure less the 6-month figure.Report this figure(3.4)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$3.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure(26.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$26.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure(18.2)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$18.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001628280-25-038860. Derived: 6-month figure less the 3-month figure.Report this figure(28.5)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$28.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001001233-25-000024. Derived: 9-month figure less the 6-month figure.Report this figure(24.4)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$24.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure(19.3)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$19.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure
Capital expenditure$m5.5Capital expenditure, Q2 FY2023, three months to 2023-06-30$5.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-08-06, accession 0001628280-24-035165. Derived: 6-month figure less the 3-month figure.Report this figure2.7Capital expenditure, Q3 FY2023, three months to 2023-09-30$2.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0001628280-24-047102. Derived: 9-month figure less the 6-month figure.Report this figure2.7Capital expenditure, Q4 FY2023, three months to 2023-12-31$2.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-17, accession 0001628280-25-013088. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-05-09, accession 0001628280-24-022194.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0001628280-25-038860. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2024, three months to 2024-09-30$115.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001001233-25-000024. Derived: 9-month figure less the 6-month figure.Report this figure0.2Capital expenditure, Q4 FY2024, three months to 2024-12-31$152.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$24.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0001628280-25-038860. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$64.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001001233-25-000024. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$14.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-30, accession 0001628280-26-022029. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$13.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure

Shares

Diluted shares (weighted)389.62m, Q1 FY2026
Sangamo Therapeutics, Inc, shares, quarterly
Line itemUnitQ2 FY20222022-06-30Q3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31
Diluted shares (weighted)m shares148Diluted shares (weighted), Q2 FY2022, three months to 2022-06-30148,158,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-08-08, accession 0001628280-23-028200.Report this figure158Diluted shares (weighted), Q3 FY2022, three months to 2022-09-30158,042,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-01, accession 0001628280-23-035989.Report this figure169Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31169,181,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001628280-24-022194.Report this figure174Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30174,325,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-06, accession 0001628280-24-035165.Report this figure177Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30177,171,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-12, accession 0001628280-24-047102.Report this figure180Diluted shares (weighted), Q1 FY2024, three months to 2024-03-31180,342,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001628280-25-024650.Report this figure204Diluted shares (weighted), Q2 FY2024, three months to 2024-06-30203,946,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure214Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30214,325,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure220Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31220,269,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure257Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30256,950,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001628280-25-038860.Report this figure304Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30304,268,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001001233-25-000024.Report this figure390Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31389,616,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure

Shares outstanding: 414.29mShares outstanding, period not labelled, at 2026-05-11414,288,847 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-05-14, accession 0001628280-26-035067.Report this figure at May 11, 2026, from the cover of the 10-Q filed May 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. Listed shows no prices and gives no investment advice.